Article Details

AstraZeneca inks $760 million deal with Swiss firm Neurimmune for antibody drug - WTVB

Retrieved on: 2022-03-01 08:46:11

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca inks $760 million deal with Swiss firm Neurimmune for antibody drug - WTVB. View article details on hiswai:

Excerpt

AstraZeneca's rare diseases unit Alexion and Neurimmune will work on evaluating NI006, a monoclonal antibody for the treatment of transthyretin ...

Article found on: wtvbam.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up